Full Text
Cost-Utility Analysis of Certolizumab Pegol for the Treatment of Active Psoriatic Arthritis in GREECE

Abstract

Authors

C Tzanetakos D Vassilopoulos G Kourlaba P Christou N Maniadakis

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×